Last week’s Xconomy New York Life Sciences 2031 symposium produced lots of articulate speculation about the distant future of biotechnology and its related industries. But for those of us who work or invest in life sciences, the discussion did little to answer the pressing question: what can and should we do now to meet the … Continue reading “Life Sciences 2031: What about 2011?”
Author: David Sable
David Sable directs healthcare and life science investing for the Special Situations Funds in New York and is portfolio manager of the Special Situations Life Sciences Fund. After graduating from the Wharton School and the University of Pennsylvania School of Medicine, residency in obstetrics and gynecology at New York Hospital Cornell Medical Center, fellowship at Brigham and Women's Hospital, and clinical practice at Harvard Medical School and MIT, he co-founded the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey. After leaving clinical medicine at age 43, Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations group. He is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences.